The empliciti market research report is one of a series of new reports that provides empliciti market statistics, including the empliciti industry global market size, regional shares, competitors with the empliciti market share, detailed empliciti market segments, market trends, and opportunities, and any further data you may need to thrive in the empliciti industry. This empliciti market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.
The growth in the forecast period can be attributed to expansion into new indications, rising incidence of multiple myeloma, regulatory approvals for additional indications, and improved patient access programs. Major trends in the forecast period include advancements in immuno-oncology, growing demand for personalized medicine, cell and gene therapy developments, immuno-modulatory drug (imid) integration, and enhanced delivery systems.
The increasing prevalence of multiple myeloma is expected to drive the growth of the Empliciti market. Multiple myeloma is a form of cancer affecting plasma cells, a type of white blood cell found in bone marrow, which leads to abnormal cell growth and can damage bones, kidneys, and the immune system. The rise in multiple myeloma cases is influenced by factors such as an aging population and better diagnostic techniques. Empliciti targets the SLAMF7 protein found on both myeloma and natural killer (NK) cells, enhancing the immune system's ability to recognize and destroy cancer cells. It boosts NK cell activity and supports antibody-dependent cellular cytotoxicity (ADCC), which helps slow the progression of the disease when used alongside other treatments. For instance, in August 2024, the American Cancer Society reported that approximately 35,780 new cases of multiple myeloma were diagnosed in the United States in 2024, with 19,520 cases in men and 16,260 in women. Around 12,540 deaths are expected, including 7,020 men and 5,520 women. This increase in multiple myeloma cases will contribute to the growth of the Empliciti market.
The rising demand for targeted cancer therapies is significantly driving the growth of the Empliciti market. These therapies specifically target cancer cells by identifying certain molecular markers, reducing damage to healthy cells. The demand for such therapies is growing due to advancements in precision medicine, the increasing prevalence of cancer, improved treatment efficacy, and a greater emphasis on minimizing side effects. Empliciti targets SLAMF7, a protein present on multiple myeloma and immune cells, enhancing the immune system’s ability to attack cancer. This dual targeting approach enhances precision while sparing healthy tissues. For example, in June 2024, the Royal College of Radiologists reported a 6-8% increase in the demand for systemic anti-cancer therapies (SACT), including chemotherapy, in 2023. This growing interest in targeted cancer therapies will continue to drive the Empliciti market.
Rising healthcare expenditure is expected to accelerate the growth of the Empliciti market. Healthcare expenditure refers to the total financial resources allocated to healthcare services, including medical treatments, infrastructure, and personnel. The increase in healthcare spending is driven by factors such as an aging population, the growing prevalence of chronic diseases, advancements in medical technology, and the demand for improved healthcare services. Higher healthcare expenditure boosts investment in advanced cancer therapies such as Empliciti, enabling broader access to these innovative treatments. This investment also strengthens healthcare infrastructure and supports research, improving cancer care outcomes. For instance, the Office for National Statistics in May 2024 reported a 5.6% increase in healthcare expenditure from 2022 to 2023, a notable rise compared to the 0.9% increase in 2022. As healthcare spending continues to rise, it will drive the growth of the Empliciti market.
The key player in the empliciti market is Bristol-Myers Squibb Company.
North America was the largest region in the empliciti market in 2024. The regions covered in empliciti report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the empliciti market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Empliciti (elotuzumab) is a prescription medication used in the treatment of multiple myeloma, a type of cancer that affects plasma cells in the bone marrow. Classified as a monoclonal antibody, it works by targeting and enhancing the immune system’s ability to fight cancer cells.
Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.
The main indications for Empliciti include active multiple myeloma and smoldering multiple myeloma. Active myeloma is a progressing blood cancer characterized by CRAB criteria, which indicates damage to bones, red blood cells, kidneys, or myeloma-defining events identified through predictive markers or imaging. Empliciti is part of several drug classes, including monoclonal antibodies, immunomodulatory agents, and proteasome inhibitors. It is distributed through multiple channels, including hospital pharmacies, retail pharmacies, and online pharmacies, and is used by various end users, such as hospitals, clinics, ambulatory care facilities, and home care providers.
The empliciti market consists of sales of combination therapies, and injections. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
The growth in the forecast period can be attributed to expansion into new indications, rising incidence of multiple myeloma, regulatory approvals for additional indications, and improved patient access programs. Major trends in the forecast period include advancements in immuno-oncology, growing demand for personalized medicine, cell and gene therapy developments, immuno-modulatory drug (imid) integration, and enhanced delivery systems.
The increasing prevalence of multiple myeloma is expected to drive the growth of the Empliciti market. Multiple myeloma is a form of cancer affecting plasma cells, a type of white blood cell found in bone marrow, which leads to abnormal cell growth and can damage bones, kidneys, and the immune system. The rise in multiple myeloma cases is influenced by factors such as an aging population and better diagnostic techniques. Empliciti targets the SLAMF7 protein found on both myeloma and natural killer (NK) cells, enhancing the immune system's ability to recognize and destroy cancer cells. It boosts NK cell activity and supports antibody-dependent cellular cytotoxicity (ADCC), which helps slow the progression of the disease when used alongside other treatments. For instance, in August 2024, the American Cancer Society reported that approximately 35,780 new cases of multiple myeloma were diagnosed in the United States in 2024, with 19,520 cases in men and 16,260 in women. Around 12,540 deaths are expected, including 7,020 men and 5,520 women. This increase in multiple myeloma cases will contribute to the growth of the Empliciti market.
The rising demand for targeted cancer therapies is significantly driving the growth of the Empliciti market. These therapies specifically target cancer cells by identifying certain molecular markers, reducing damage to healthy cells. The demand for such therapies is growing due to advancements in precision medicine, the increasing prevalence of cancer, improved treatment efficacy, and a greater emphasis on minimizing side effects. Empliciti targets SLAMF7, a protein present on multiple myeloma and immune cells, enhancing the immune system’s ability to attack cancer. This dual targeting approach enhances precision while sparing healthy tissues. For example, in June 2024, the Royal College of Radiologists reported a 6-8% increase in the demand for systemic anti-cancer therapies (SACT), including chemotherapy, in 2023. This growing interest in targeted cancer therapies will continue to drive the Empliciti market.
Rising healthcare expenditure is expected to accelerate the growth of the Empliciti market. Healthcare expenditure refers to the total financial resources allocated to healthcare services, including medical treatments, infrastructure, and personnel. The increase in healthcare spending is driven by factors such as an aging population, the growing prevalence of chronic diseases, advancements in medical technology, and the demand for improved healthcare services. Higher healthcare expenditure boosts investment in advanced cancer therapies such as Empliciti, enabling broader access to these innovative treatments. This investment also strengthens healthcare infrastructure and supports research, improving cancer care outcomes. For instance, the Office for National Statistics in May 2024 reported a 5.6% increase in healthcare expenditure from 2022 to 2023, a notable rise compared to the 0.9% increase in 2022. As healthcare spending continues to rise, it will drive the growth of the Empliciti market.
The key player in the empliciti market is Bristol-Myers Squibb Company.
North America was the largest region in the empliciti market in 2024. The regions covered in empliciti report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the empliciti market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Empliciti (elotuzumab) is a prescription medication used in the treatment of multiple myeloma, a type of cancer that affects plasma cells in the bone marrow. Classified as a monoclonal antibody, it works by targeting and enhancing the immune system’s ability to fight cancer cells.
Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.
The main indications for Empliciti include active multiple myeloma and smoldering multiple myeloma. Active myeloma is a progressing blood cancer characterized by CRAB criteria, which indicates damage to bones, red blood cells, kidneys, or myeloma-defining events identified through predictive markers or imaging. Empliciti is part of several drug classes, including monoclonal antibodies, immunomodulatory agents, and proteasome inhibitors. It is distributed through multiple channels, including hospital pharmacies, retail pharmacies, and online pharmacies, and is used by various end users, such as hospitals, clinics, ambulatory care facilities, and home care providers.
The empliciti market consists of sales of combination therapies, and injections. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
Table of Contents
1. Executive Summary2. Empliciti Market Characteristics4. Empliciti Market Trends And Strategies5. Empliciti Market -Macro Economic Scenario Including the Impact of Interest Rates, Inflation, Geopolitics, and the Recovery from COVID-19 on the Market7. Global Empliciti Pricing Analysis & Forecasts30. Global Empliciti Market Competitive Benchmarking And Dashboard31. Key Mergers And Acquisitions In The Empliciti Market32. Recent Developments In The Empliciti Market
3. Empliciti Market Biologic Drug Characteristics
6. Global Empliciti Growth Analysis And Strategic Analysis Framework
8. Empliciti Market Segmentation
9. Global Empliciti Epidemiology Of Clinical Indications
10. Empliciti Market Regional And Country Analysis
11. Asia-Pacific Empliciti Market
12. China Empliciti Market
13. India Empliciti Market
14. Japan Empliciti Market
15. Australia Empliciti Market
16. South Korea Empliciti Market
17. Western Europe Empliciti Market
18. UK Empliciti Market
19. Germany Empliciti Market
20. France Empliciti Market
21. Eastern Europe Empliciti Market
22. North America Empliciti Market
23. USA Empliciti Market
24. Canada Empliciti Market
25. South America Empliciti Market
26. Middle East Empliciti Market
27. Africa Empliciti Market
28. Empliciti Market Competitive Landscape And Company Profiles
29. Global Empliciti Market Pipeline Analysis
33. Empliciti Market High Potential Countries, Segments and Strategies
34. Appendix
Executive Summary
Empliciti Global Market Report 2025 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses on empliciti market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
- Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for empliciti ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The empliciti market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include:
- The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:
1) By Indication: Active Multiple Myeloma; Smoldering Multiple Myeloma2) By Drug Class: Monoclonal Antibodies; Immunomodulatory Agents; Proteasome Inhibitors
3) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies
4) By End Use: Hospitals; Clinics; Ambulatory Care; Home Care
Key Companies Profiled: Bristol-Myers Squibb Company
Countries: Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: PDF, Word and Excel Data Dashboard.
Companies Mentioned
- Bristol-Myers Squibb Company
